Rocket Pharmaceuticals Inc [RCKT] stock is trading at $3.73, down -0.53%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RCKT shares have gain 23.10% over the last week, with a monthly amount glided 11.01%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rocket Pharmaceuticals Inc [NASDAQ: RCKT] stock has seen the most recent analyst activity on August 20, 2025, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $10 for it. Previously, BofA Securities downgraded its rating to Neutral on July 25, 2025, and kept the price target unchanged to $4. On May 30, 2025, downgrade downgraded it’s rating to In-line but maintained its price target of $5 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight but stick to its price target of $7 on May 28, 2025. Leerink Partners downgraded its rating to a Market Perform but $8 remained the price target by the analyst firm on May 28, 2025. JP Morgan downgraded its rating to Neutral for this stock on May 28, 2025. In a note dated May 28, 2025, Jefferies downgraded an Hold rating on this stock but restated the target price of $2.50.
Rocket Pharmaceuticals Inc [RCKT] stock has fluctuated between $2.19 and $22.01 over the past year. Currently, Wall Street analysts expect the stock to reach $2.25 within the next 12 months. Rocket Pharmaceuticals Inc [NASDAQ: RCKT] shares were valued at $3.73 at the most recent close of the market. An investor can expect a potential drop of -39.68% based on the average RCKT price forecast.
Analyzing the RCKT fundamentals
Gross Profit Margin for this corporation currently stands at -0.36% with Operating Profit Margin at -29.14%, Pretax Profit Margin comes in at -28.01%, and Net Profit Margin reading is -28.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.61, Equity is -0.66 and Total Capital is -0.71. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.60 points at the first support level, and at 3.46 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.87, and for the 2nd resistance point, it is at 4.01.
Ratios To Look Out For
For context, Rocket Pharmaceuticals Inc’s Current Ratio is 6.39. As well, the Quick Ratio is 6.39, while the Cash Ratio is 0.76.
Transactions by insiders
Recent insider trading involved Militello John, that happened on Aug 18 ’25 when 699.0 shares were sold. Militello John completed a deal on Aug 19 ’25 to sell 361.0 shares. Meanwhile, Schwartz Jonathan David sold 1680.0 shares on Aug 18 ’25.
